STOCK TITAN

[SCHEDULE 13G/A] Trevi Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Viking Global Investors and affiliated entities report beneficial ownership of 7,505,694 shares of Trevi Therapeutics (TRVI), representing 5.9% of the common stock. The holdings consist of 1,543,000 shares directly owned by two affiliated entities (1,033,810 by VGOP and 509,190 by VGOD) and 5,962,694 shares issuable upon exercise of pre-funded warrants exercisable at $0.001 per share. The filing clarifies the ownership chain through multiple Delaware and Cayman entities and notes shared voting and dispositive power among the reporting persons, including O. Andreas Halvorsen, David C. Ott and Rose S. Shabet. The statement affirms these securities were not acquired to change or influence control of the issuer.

Viking Global Investors e società collegate dichiarano la titolarità effettiva di 7.505.694 azioni di Trevi Therapeutics (TRVI), pari al 5,9% del capitale ordinario. La partecipazione include 1.543.000 azioni detenute direttamente da due entità affiliate (1.033.810 da VGOP e 509.190 da VGOD) e 5.962.694 azioni derivanti dall'esercizio di warrant pre-finanziati esercitabili a 0,001 dollari per azione. La comunicazione descrive la catena di controllo attraverso più entità del Delaware e delle Cayman e indica il comune potere di voto e di disposizione tra i soggetti comunicanti, tra cui O. Andreas Halvorsen, David C. Ott e Rose S. Shabet. La dichiarazione precisa che tali titoli non sono stati acquisiti con l'intento di modificare o influenzare il controllo dell'emittente.

Viking Global Investors y entidades vinculadas informan la propiedad beneficiaria de 7.505.694 acciones de Trevi Therapeutics (TRVI), que representan el 5,9% del capital social ordinario. Las tenencias comprenden 1.543.000 acciones propiedad directa de dos entidades afiliadas (1.033.810 de VGOP y 509.190 de VGOD) y 5.962.694 acciones susceptibles de emitirse mediante el ejercicio de warrants prefinanciados ejercitables a 0,001 USD por acción. La presentación aclara la cadena de propiedad a través de múltiples entidades de Delaware y las Islas Caimán y señala el poder conjunto de voto y disposición entre las personas informantes, incluidos O. Andreas Halvorsen, David C. Ott y Rose S. Shabet. La declaración afirma que estos valores no se adquirieron para cambiar o influir en el control del emisor.

Viking Global Investors 및 계열사는 Trevi Therapeutics(TRVI) 주식 7,505,694주(보통주 기준 5.9%)의 실질적 소유를 보고했습니다. 보유 내역은 두 계열사가 직접 보유한 1,543,000주(VGOP 1,033,810주, VGOD 509,190주)와 주당 0.001달러에 행사 가능한 프리펀디드 워런트로 인해 발행될 수 있는 5,962,694주로 구성됩니다. 신고서는 델라웨어 및 케이먼제도의 여러 법인을 통한 소유 구조를 명확히 하고, O. Andreas Halvorsen, David C. Ott 및 Rose S. Shabet을 포함한 보고인들 간의 공동 의결권 및 처분권을 명시합니다. 성명서는 이 증권들이 발행사의 지배권을 변경하거나 영향력을 행사하기 위해 취득된 것이 아님을 확인합니다.

Viking Global Investors et des entités affiliées déclarent la propriété bénéficiaire de 7 505 694 actions de Trevi Therapeutics (TRVI), soit 5,9 % du capital social ordinaire. Les avoirs se composent de 1 543 000 actions détenues directement par deux entités affiliées (1 033 810 par VGOP et 509 190 par VGOD) et de 5 962 694 actions susceptibles d'être émises lors de l'exercice de bons d'achat préfinancés exerçables à 0,001 $ par action. Le dépôt précise la chaîne de propriété passant par plusieurs entités du Delaware et des îles Caïmans et indique des pouvoirs de vote et de disposition partagés entre les déclarants, notamment O. Andreas Halvorsen, David C. Ott et Rose S. Shabet. La déclaration affirme que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Viking Global Investors und verbundene Einheiten melden das wirtschaftliche Eigentum an 7.505.694 Aktien von Trevi Therapeutics (TRVI), was 5,9 % des Stammkapitals entspricht. Die Bestände setzen sich aus 1.543.000 direkt von zwei verbundenen Einheiten gehaltenen Aktien zusammen (1.033.810 von VGOP und 509.190 von VGOD) sowie 5.962.694 Aktien, die bei Ausübung vordefinierter, vorfinanzierter Warrants zu je 0,001 USD ausgegeben werden können. Die Meldung erläutert die Eigentumskette über mehrere Delaware- und Cayman-Island-Gesellschaften und weist auf gemeinsames Stimm- und Verfügungsrecht der meldepflichtigen Personen hin, darunter O. Andreas Halvorsen, David C. Ott und Rose S. Shabet. Die Erklärung stellt klar, dass diese Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu verändern oder zu beeinflussen.

Positive
  • Material passive stake disclosed: Viking Global Investors and affiliates beneficially own 7,505,694 shares (5.9%) of TRVI.
  • Warrant transparency: Filing specifies 5,962,694 shares are exercisable upon exercise of pre-funded warrants at $0.001 per share.
  • Clear ownership chain: The statement details the fund structure and identifies persons with shared voting and dispositive authority, including Halvorsen, Ott and Shabet.
  • Filed as passive (Schedule 13G/A): Reporting persons certify the position is not for changing or influencing control of the issuer.
Negative
  • None.

Insights

TL;DR: Viking Global-affiliated funds hold 5.9% of TRVI, combining direct shares and warrant exposure, a material passive stake.

The Schedule 13G/A discloses a 5.9% economic and voting interest in Trevi Therapeutics via direct holdings and exercisable pre-funded warrants. For investors, the key fact is the combined exposure of 7,505,694 shares, of which 5,962,694 are currently exercisable warrants, which could increase voting shares if exercised. The filing is presented under passive-investor rules and expressly states the position is not intended to influence control. This is a material disclosure by size but framed as non-activist by the reporting persons.

TL;DR: Multiple affiliated entities and named executives share voting/dispositive power over a 5.9% stake, disclosed under Schedule 13G/A.

The document maps the control chain: VGI provides managerial services and may be deemed the beneficial owner under Rule 13d-3, while Opportunities Parent and several GP/LP entities hold and control the underlying economic interests. Executive Committee members Halvorsen, Ott and Shabet are identified as having shared authority, but the certification confirms no intent to change control. From a governance perspective, this is a routine but material ownership disclosure highlighting the practical delegation of voting and disposition across fund structures.

Viking Global Investors e società collegate dichiarano la titolarità effettiva di 7.505.694 azioni di Trevi Therapeutics (TRVI), pari al 5,9% del capitale ordinario. La partecipazione include 1.543.000 azioni detenute direttamente da due entità affiliate (1.033.810 da VGOP e 509.190 da VGOD) e 5.962.694 azioni derivanti dall'esercizio di warrant pre-finanziati esercitabili a 0,001 dollari per azione. La comunicazione descrive la catena di controllo attraverso più entità del Delaware e delle Cayman e indica il comune potere di voto e di disposizione tra i soggetti comunicanti, tra cui O. Andreas Halvorsen, David C. Ott e Rose S. Shabet. La dichiarazione precisa che tali titoli non sono stati acquisiti con l'intento di modificare o influenzare il controllo dell'emittente.

Viking Global Investors y entidades vinculadas informan la propiedad beneficiaria de 7.505.694 acciones de Trevi Therapeutics (TRVI), que representan el 5,9% del capital social ordinario. Las tenencias comprenden 1.543.000 acciones propiedad directa de dos entidades afiliadas (1.033.810 de VGOP y 509.190 de VGOD) y 5.962.694 acciones susceptibles de emitirse mediante el ejercicio de warrants prefinanciados ejercitables a 0,001 USD por acción. La presentación aclara la cadena de propiedad a través de múltiples entidades de Delaware y las Islas Caimán y señala el poder conjunto de voto y disposición entre las personas informantes, incluidos O. Andreas Halvorsen, David C. Ott y Rose S. Shabet. La declaración afirma que estos valores no se adquirieron para cambiar o influir en el control del emisor.

Viking Global Investors 및 계열사는 Trevi Therapeutics(TRVI) 주식 7,505,694주(보통주 기준 5.9%)의 실질적 소유를 보고했습니다. 보유 내역은 두 계열사가 직접 보유한 1,543,000주(VGOP 1,033,810주, VGOD 509,190주)와 주당 0.001달러에 행사 가능한 프리펀디드 워런트로 인해 발행될 수 있는 5,962,694주로 구성됩니다. 신고서는 델라웨어 및 케이먼제도의 여러 법인을 통한 소유 구조를 명확히 하고, O. Andreas Halvorsen, David C. Ott 및 Rose S. Shabet을 포함한 보고인들 간의 공동 의결권 및 처분권을 명시합니다. 성명서는 이 증권들이 발행사의 지배권을 변경하거나 영향력을 행사하기 위해 취득된 것이 아님을 확인합니다.

Viking Global Investors et des entités affiliées déclarent la propriété bénéficiaire de 7 505 694 actions de Trevi Therapeutics (TRVI), soit 5,9 % du capital social ordinaire. Les avoirs se composent de 1 543 000 actions détenues directement par deux entités affiliées (1 033 810 par VGOP et 509 190 par VGOD) et de 5 962 694 actions susceptibles d'être émises lors de l'exercice de bons d'achat préfinancés exerçables à 0,001 $ par action. Le dépôt précise la chaîne de propriété passant par plusieurs entités du Delaware et des îles Caïmans et indique des pouvoirs de vote et de disposition partagés entre les déclarants, notamment O. Andreas Halvorsen, David C. Ott et Rose S. Shabet. La déclaration affirme que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Viking Global Investors und verbundene Einheiten melden das wirtschaftliche Eigentum an 7.505.694 Aktien von Trevi Therapeutics (TRVI), was 5,9 % des Stammkapitals entspricht. Die Bestände setzen sich aus 1.543.000 direkt von zwei verbundenen Einheiten gehaltenen Aktien zusammen (1.033.810 von VGOP und 509.190 von VGOD) sowie 5.962.694 Aktien, die bei Ausübung vordefinierter, vorfinanzierter Warrants zu je 0,001 USD ausgegeben werden können. Die Meldung erläutert die Eigentumskette über mehrere Delaware- und Cayman-Island-Gesellschaften und weist auf gemeinsames Stimm- und Verfügungsrecht der meldepflichtigen Personen hin, darunter O. Andreas Halvorsen, David C. Ott und Rose S. Shabet. Die Erklärung stellt klar, dass diese Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu verändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown (Aggregator) LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
Date:08/14/2025
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:08/14/2025
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:08/14/2025
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:08/14/2025

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

How many Trevi Therapeutics (TRVI) shares does Viking Global beneficially own?

The reporting persons beneficially own 7,505,694 shares of Trevi Therapeutics common stock, representing 5.9% of the class.

How much of the Viking Global position in TRVI is from exercisable warrants?

The filing states 5,962,694 shares are issuable upon exercise of pre-funded warrants exercisable at $0.001 per share.

Do the reporting persons intend to influence control of Trevi Therapeutics?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

Which individuals are identified as having shared voting authority over the TRVI stake?

O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are named as Executive Committee members with shared authority to vote and dispose of the shares.

What is the total share count used to calculate the 5.9% ownership percentage?

The percentage is based on 121,775,753 shares outstanding as of June 30, 2025, plus the 5,962,694 shares issuable upon exercise of the warrants.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

925.50M
109.43M
0.75%
79.28%
8.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN